The YieldMax PLTR Option Income Strategy ETF (NYSEARCA: PLTY ) is one in a series of YieldMax ETFs that is based on a covered call selling strategy on a single name. In this case, Palantir Technologies Inc. (Bram de Haas brings 15 years of investing experience to the table and has over 5 years of experience managing a Euro hedge fund. He is also a former professional poker player and utilizes his bundle of risk management skills to uncover lucrative investments based on special situations.Analyst’s Disclosu ...

Distribution Announcement - Canadian Banc Corp. declares a monthly distribution of $0.13700 for each Class A share and $0.05375 for each Preferred share, payable on June 10, 2025, to shareholders on record as of May 30, 2025 [1][5] Dividend Policy - The monthly dividend for Class A shares is determined by a 15% annualized rate based on the volume weighted average market price (VWAP) over the last 3 trading days of the preceding month, resulting in a dividend of $0.13700 per share based on a VWAP of $10.96 [2] Shareholder Returns - Since inception, Class A shareholders have received a total of $23.81 per share, while Preferred shareholders have received a total of $11.16 per share, leading to a combined total of $34.97 [3] Investment Portfolio - The Company invests in a portfolio of six publicly traded Canadian banks, including Bank of Montreal, Canadian Imperial Bank of Commerce, National Bank of Canada, Royal Bank of Canada, Bank of Nova Scotia, and Toronto-Dominion Bank, with share weights expected to range between 5-20% [4] Additional Returns Strategy - To generate additional returns above the dividend income, the Company engages in a selective covered call writing program [4]

Group 1 - The biotech forum has seen significant discussions around profitable buy-write or covered call strategies on selected biotech stocks in recent months [1] - Travere Therapeutics, Inc. (NASDAQ: TVTX) is highlighted for its impressive sales growth in Q1, despite a recent pullback in stock price and a notable reduction in losses [2] - The investing group, The Biotech Forum, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat for trade ideas and weekly market commentary [2]

Group 1 - The article discusses the author's long-term investment approach, focusing on REITs, preferred stocks, and high-yield bonds, which began in high school in 2011 [1] - The author has recently combined long stock positions with covered calls and cash secured puts, indicating a strategy that balances risk and return [1] - The primary focus of the author's coverage on Seeking Alpha includes REITs and financials, with occasional insights on ETFs and macro-driven stock ideas [1]

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, I am putting Avadel Pharmaceuticals (NASDAQ: AVDL ) back in the spotlight. We last looked at this promising biopharma concern just over three months ago. However, there has ...

I'm quite familiar with UnitedHealthcare "UNH" (NYSE: UNH ), as the healthcare giant towers over the skyline of my home state, Connecticut. I also have a confession to make. I recently purchased UNH's stock atAre You Getting The Returns You Want? Invest alongside the Financial Prophet's All-Weather Portfolio (2024 69% return) and achieve optimal results in any market.The Daily Prophet Report provides crucial information before the opening bell rings each morning.Implement my Covered Call Dividend Plan and e ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several quarters. To see what I am targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Mid-cap oncology concern Exelixis, Inc. (NASDAQ: EXEL ) posted more than solid first-quarter results after the bell on Tuesday. Management also raised forward guidance significantly. The company is going through somewh ...

Group 1 - The article discusses the recent focus on covered call opportunities within the biotech sector, particularly in the context of ACADIA Pharmaceuticals Inc. [1] - ACADIA Pharmaceuticals has been revisited due to a significant influx of new data points since the last analysis in March, indicating ongoing developments in the company [2] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live discussions and weekly updates on market commentary and portfolio performance [2] Group 2 - The author has a beneficial long position in ACADIA Pharmaceuticals, indicating a personal investment interest in the company's stock [3] - The article emphasizes that past performance does not guarantee future results, highlighting the inherent uncertainties in investment decisions [4]

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just join our community at The Biotech Forum by clicking HERE .Today, I am putting a medical solution and medical device provider Solventum Corporation (NYSE: SOLV ) for the first time since my initial article on this recent spinoff early l ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are going to put Omnicell, Inc. ( OMCL ) , a small-cap medical technology solutions provider in the spotlight for the first time. The company just posted its Q1 results o ...